Display options
Share it on

Int J Mol Sci. 2021 Nov 30;22(23). doi: 10.3390/ijms222312945.

Role of ANGPTL8 in NAFLD Improvement after Bariatric Surgery in Experimental and Human Obesity.

International journal of molecular sciences

Carolina M Perdomo, Javier Gómez-Ambrosi, Sara Becerril, Víctor Valentí, Rafael Moncada, Eva M Fernández-Sáez, Leire Méndez-Giménez, Silvia Ezquerro, Victoria Catalán, Camilo Silva, Javier Escalada, Gema Frühbeck, Amaia Rodríguez

Affiliations

  1. Department of Endocrinology & Nutrition, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
  2. Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
  3. CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.
  4. Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
  5. Department of Surgery, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
  6. Department of Anesthesia, Clínica Universidad de Navarra, 31008 Pamplona, Spain.

PMID: 34884755 DOI: 10.3390/ijms222312945

Abstract

Angiopoietin-like protein 8 (ANGPTL8) is an hepatokine altered in several metabolic conditions, such as obesity, type 2 diabetes, dyslipidemia and nonalcoholic fatty liver disease (NAFLD). We sought to explore whether ANGPTL8 is involved in NAFLD amelioration after bariatric surgery in experimental models and patients with severe obesity. Plasma ANGPTL8 was measured in 170 individuals before and 6 months after bariatric surgery. Hepatic ANGPTL8 expression was evaluated in liver biopsies of patients with severe obesity undergoing bariatric surgery with available liver pathology analysis (

Keywords: NAFLD; angiopoietin-like protein 8; bariatric surgery; lipogenesis; obesity

Publication Types

Grant support